Navigation Links
Webcast Alert: Isis Pharmaceuticals' Cardiovascular Program Review
Date:11/6/2008

NEW ORLEANS and CARLSBAD, Calif., Nov. 6

/PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

What: Isis' cardiovascular program review of development and

late-stage research candidates, including presentations

from:

-- Dr. Erik Stroes reporting top line data from an ongoing

Phase 2 mipomersen liver imaging study

-- Dr. Evan Stein providing an update on an open-label

extension study of mipomersen in subjects with familial

hypercholesterolemia

When: Monday, November 10, 2008, at 6:00 p.m. CT (4:00 p.m.

PT/7:00 p.m. ET)

Where: http://www.isispharm.com

How: Live on the Internet. Simply log onto the website listed

above.

Contacts: Kristina Lemonidis

Associate Director, Corporate Development

Isis Pharmaceuticals, Inc.

(760) 603-2490

Amy Blackley, Ph.D.

Manager, Corporate Communications

Isis Pharmaceuticals, Inc.

(760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. GNC Schedules Conference Call and Webcast to Report 3rd Quarter 2008 Financial Results
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. STERIS Corporation Announces Webcast of Analyst Conference
5. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Third Quarter 2008 Financial Results Call Set for November 11
6. Webcast Alert: Heska Announces Third Quarter 2008 Earnings Conference Call Webcast
7. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
8. Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Fourth Quarter and Year End Earnings Webcast
9. Sunrise to Host Conference Call and Webcast to Discuss the Companys Financial Results for the Third Quarter 2008
10. Webcast Alert: Air Methods Corporation Announces Third Quarter 2008 Financial Results
11. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest ... the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity drive ... rare and deadly chromosome abnormality. , After struggling since birth with several health ...
(Date:10/13/2017)... Pekin, IL (PRWEB) , ... October 13, 2017 ... ... Foundation, which established the certification process to promote standards of excellence for the ... iaedp™ Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at ...
(Date:10/13/2017)... ... 2017 , ... Many families have long-term insurance that covers care for a ... waiver for care if the client has a cognitive impairment diagnosis. , “What ... is often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... be giving viewers the lowdown on sciatica in a new episode of "Success ... focuses on current events and innovation and investigates each subject in-depth with passion ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/22/2017)... 22, 2017 AVACEN Medical (AVACEN) announced that ... successfully helping those with the widespread pain associated with ... Amanda in Essex, England commented, ... hair, experiencing no sleep at all, tremendous pain, with ... cannot recommend [the AVACEN 100] enough, how this has ...
(Date:9/19/2017)... Sept. 19, 2017   ZirMed Inc ., a recognized ... announced that it has been ranked #1 by its users ... Rankings 2017 User Survey. ZirMed was recognized as the ... hospitals and medical centers over 200 beds and holds one ... technology user survey history. ...
Breaking Medicine Technology: